Liminal BioSciences Inc. PFSCF

RE:RE:for the spammers and their 'lawsuit', read this

[PLITheOne]

Whoa! Served on March 2nd!!!!
Investors were just informed!
Three weeks of silence from Liminal on something that will crush them. Sounds in character, Liminal wanted to get their affairs in order prior to informing investors. Looks like the even hid it from their year end! Knowing who these predators are should guide the way  

Sterling547 wrote: Hey realDUMBStock, Reading comprehension must not be your strong suit. What you posted, an AMF ruling from 2019 has nothing to do with the $700 million dollars lawsuit against Liminal in US civil court. Too bad there is no US crimial RICO case against Liminal/PLI. Then all the slick pumpers on this board who had diner/meetings with Pierre Laurin would be exposed. There should also be a US criminal RICO case against EEStor/FuelPositive Corp. because many of the same characters who pumped PLI pumped EEStor.

Make sure to read this:

"On March 2, 2021, we were served with an action instituted by multiple individual shareholder plaintiffs (the “Plaintiffs”) against the Company, Structured Alpha LP (“SALP”), Thomvest Asset Management (“Thomvest”), Consonance Capital Management LP (“Consonance”), as well as the directors (the “Directors”) that were on the Company’s Board on March 31, 2019 or on April 15, 2019 and certain officers of the Company (the “D&Os”, together with Liminal, SALP, Thomvest and Consonance, the “Defendants”)."
 

realstocky wrote:

AMF already ruled...in 2019, lmnl is cleared..since 2019:)

Just buy your shares, will be back to 20$ ahead of riplazym green light by FDA, then more on distribution deal...this will all happen next couple of months.(see my last 2 posts)

 

AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019

PRNewswire 28-Nov-2019 4:40 PM

LAVAL, QC, ROCKVILLE, MD and CAMBRIDGE, United Kingdom, Nov. 28, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ:LMNL) (TSX:LMNL) ( "Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, acknowledges the press release issued today by the Autorit des Marchs Financiers ("AMF") in which the AMF announced that after a thorough investigation, the AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019. The AMF is the regulatory and oversight body for Qubec's financial sector.

"We are pleased that the AMF has completed its review and concluded that it did not identify any violation or breach of securities regulation in the context of our refinancing transactions", stated Kenneth Galbraith, the Chief Executive Officer of Liminal BioSciences. "We have been cooperative and transparent with AMF throughout the review and look forward to focusing our efforts on developing and commercializing new medicines that may address serious unmet healthcare needs of patients around the world."

In April 2019, the Company completed a series of refinancing transactions, which were subject to the prior review and approval of the Toronto Stock Exchange. On November 18, 2019, the common shares of Liminal BioSciences commenced trading on the NASDAQ Global Market.